Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds
AbstractTuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest number of deaths worldwide. The increased number of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years. The scenario of drug discovery becomes alarming when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compounds with potent antituberculosis activity against MDR-TB strains. Herein, active compounds against MDR-TB with minimum inhibitory concentrations (MICs) less than 11 µM and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Fernandes, G.F.S.; Man Chin, C.; Dos Santos, J.L. Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds . Pharmaceuticals 2017, 10, 51.
Fernandes GFS, Man Chin C, Dos Santos JL. Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds . Pharmaceuticals. 2017; 10(2):51.Chicago/Turabian Style
Fernandes, Guilherme F.S.; Man Chin, Chung; Dos Santos, Jean L. 2017. "Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds ." Pharmaceuticals 10, no. 2: 51.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.